The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform
Brian Walitt - One of the best experts on this subject based on the ideXlab platform.
-
Characterization of Post–exertional Malaise in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Frontiers in Neurology, 2020Co-Authors: Barbara J. Stussman, Ashley Williams, Joseph Snow, Angelique Gavin, Remle Scott, Avindra Nath, Brian WalittAbstract:Background: Myalgic encephalomyelitis/chronic fatigue syndrome is characterized by persistent and disabling fatigue, exercise intolerance, cognitive difficulty, and musculoskeletal/joint pain. Post–exertional Malaise is a worsening of these symptoms after a physical or mental exertion and is considered a central feature of the illness. Scant observations in the available literature provide qualitative assessments of post–exertional Malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome. To enhance our understanding, a series of outpatient focus groups were convened. Methods: Nine focus groups totaling 43 patients who reported being diagnosed with myalgic encephalomyelitis/chronic fatigue syndrome were held between November 2016 and August 2019. Focus groups queried post–exertional Malaise in daily life and participants' retrospective memory of post–exertional Malaise that followed an exercise provocation with a cardiopulmonary exercise test. Data analysis followed the grounded theory method to systematically code and categorize the data to find meaningful patterns. A qualitative software package was used to move text into categories during data coding. Results: A wide range of symptoms were attributed to exertion both in daily lives and following cardiopulmonary exercise testing. While three core symptoms emerged (exhaustion, cognitive difficulties, and neuromuscular complaints), participants' descriptions were notable for their unique individual variations. Of 18 participants who responded to questions centered around symptoms following a cardiopulmonary exercise test, 17 reported that symptoms started within 24 h and peaked in severity within 72 h following the cardiopulmonary exercise test. Patients described post–exertional Malaise as interfering with their ability to lead a “normal” life. Conclusion: The experience of post–exertional Malaise in myalgic encephalomyelitis/chronic fatigue syndrome varies greatly between individuals and leads to a diminished quality of life. myalgic encephalomyelitis/chronic fatigue syndrome patients describe post–exertional Malaise as all-encompassing with symptoms affecting every part of the body, difficult to predict or manage, and requiring complete bedrest to fully or partially recover. Given the extensive variability in patients, further research identifying subtypes of post–exertional Malaise could lead to better targeted therapeutic options.
-
characterization of post exertional Malaise in patients with myalgic encephalomyelitis chronic fatigue syndrome
Frontiers in Neurology, 2020Co-Authors: Barbara J. Stussman, Ashley Williams, Joseph Snow, Angelique Gavin, Remle Scott, Avindra Nath, Brian WalittAbstract:Background: Myalgic encephalomyelitis/chronic fatigue syndrome is characterized by persistent and disabling fatigue, exercise intolerance, cognitive difficulty, and musculoskeletal/joint pain. Post-exertional Malaise is a worsening of these symptoms after a physical or mental exertion and is considered a central feature of the illness. Scant observations in the available literature provide qualitative assessments of post-exertional Malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome. To enhance our understanding, a series of outpatient focus groups were convened. Methods: Nine focus groups totaling 43 patients who reported being diagnosed with myalgic encephalomyelitis/chronic fatigue syndrome were held between November 2016 and August 2019. Focus groups queried post-exertional Malaise in daily life and participants' retrospective memory of post-exertional Malaise that followed an exercise provocation with a cardiopulmonary exercise test. Data analysis followed the grounded theory method to systematically code and categorize the data to find meaningful patterns. A qualitative software package was used to move text into categories during data coding. Results: A wide range of symptoms were attributed to exertion both in daily lives and following cardiopulmonary exercise testing. While three core symptoms emerged (exhaustion, cognitive difficulties, and neuromuscular complaints), participants' descriptions were notable for their unique individual variations. Of 18 participants who responded to questions centered around symptoms following a cardiopulmonary exercise test, 17 reported that symptoms started within 24 h and peaked in severity within 72 h following the cardiopulmonary exercise test. Patients described post-exertional Malaise as interfering with their ability to lead a "normal" life. Conclusion: The experience of post-exertional Malaise in myalgic encephalomyelitis/chronic fatigue syndrome varies greatly between individuals and leads to a diminished quality of life. myalgic encephalomyelitis/chronic fatigue syndrome patients describe post-exertional Malaise as all-encompassing with symptoms affecting every part of the body, difficult to predict or manage, and requiring complete bedrest to fully or partially recover. Given the extensive variability in patients, further research identifying subtypes of post-exertional Malaise could lead to better targeted therapeutic options.
David R. Smith - One of the best experts on this subject based on the ideXlab platform.
-
Studies on the related Neotropical genera Acrogymnia Malaise and Dacrogymnia, n. gen. (Hymenoptera: Argidae)
Zootaxa, 2020Co-Authors: David R. Smith, Leonardo A. Malagón-aldanaAbstract:Twenty species of Acrogymnia Malaise and five species of Dacrogymnia Smith Malagón-Aldana, n. gen., both exclusively Neotropical genera, are treated. Acrogymnia occurs from Costa Rica south to Bolivia and southeastern Brazil and Dacrogymnia from southern Colombia to Argentina. The following species are included: Acrogymnia alagoas Smith, n. sp., A. blanki Smith, n. sp., A. brevis Smith, n. sp., A. chapada Smith, n. sp., A. clypea Smith, n. sp., A coxalis (Konow, 1906), A. deulufeuti Smith, n. sp., A. diamantinensis Malaise, 1955, A. fascia Smith, n. sp., A. krylita Smith, n. sp., A. listoni Smith, n. sp., A. lopesi Malaise, 1949, A. palama Smith, 1992, A. pauxilla (Konow, 1906), A. pereirai Smith Malagón-Aldana, n. sp., A. pulla Smith, n. sp., A. pusilla (Malaise, 1937), A. rufina Malaise,1949, A. scutimacula Malaise, 1941, A. transtillata (Konow, 1906), Dacrogymnia acella (Smith, 1992), n. comb., D. imbogea (Smith,1981), n. comb., D. australis Smith, n. sp., D. fernandezi Smith Malagón-Aldana, n. sp., and D. taegeri Smith, n. sp. An identification key for species is provided; however, association of sexes in Acrogymnia is still uncertain for several species.
-
Rediscovery of the perreyiine genus Barilochia Malaise (Hymenoptera: Pergidae) in South America.
Proceedings of the Entomological Society of Washington, 2009Co-Authors: David R. Smith, Stefan SchmidtAbstract:Abstract The sawfly genus Barilochia Malaise (Pergidae: Perreyiinae) was known from a single specimen of one species, B. brunneovirens Malaise, from San Carlos de Bariloche, Rio Negro, Argentina. A second species from Chile, B. longivalvula, n. sp., is described and illustrated. A male of Barilochia is described for the first time. The possible host plant is Nothofagus dombeyi (Coihue) (Nothofagaceae).
-
Revision of the genus Indostegia Malaise (Hymenoptera: Tenthredinidae) in India
2002Co-Authors: Vasu, Malkiat S. Saini, David R. SmithAbstract:The genus Indostegia, known only from India, includes five species, I. apicicornis Malaise, I. frontata, n. sp., I. foveata, n. sp., I. vatsi, n. sp., and I. ecarinata, n. sp. The male of I. apicicornis Malaise is described for the first time. A key is provided for the species.
-
The sawfly genus Kambaitina Malaise (Hymenoptera: Tenthredinidae) in India
2002Co-Authors: Malkiat S. Saini, David R. Smith, VasuAbstract:The southeastern Asian genus Kambaitana is reviewed. Five new species from India are described: K. clypeata, K. lineata, K. impunctata, K. pup, and K. cardiaca. Kambaitana fulvipicta Malaise from Myanmar and India is redescribed. Males of the genus are characterized for the first time. A key for all seven known species, including K. albipicta Malaise from Myanmar, is provided.
Barbara J. Stussman - One of the best experts on this subject based on the ideXlab platform.
-
Characterization of Post–exertional Malaise in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Frontiers in Neurology, 2020Co-Authors: Barbara J. Stussman, Ashley Williams, Joseph Snow, Angelique Gavin, Remle Scott, Avindra Nath, Brian WalittAbstract:Background: Myalgic encephalomyelitis/chronic fatigue syndrome is characterized by persistent and disabling fatigue, exercise intolerance, cognitive difficulty, and musculoskeletal/joint pain. Post–exertional Malaise is a worsening of these symptoms after a physical or mental exertion and is considered a central feature of the illness. Scant observations in the available literature provide qualitative assessments of post–exertional Malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome. To enhance our understanding, a series of outpatient focus groups were convened. Methods: Nine focus groups totaling 43 patients who reported being diagnosed with myalgic encephalomyelitis/chronic fatigue syndrome were held between November 2016 and August 2019. Focus groups queried post–exertional Malaise in daily life and participants' retrospective memory of post–exertional Malaise that followed an exercise provocation with a cardiopulmonary exercise test. Data analysis followed the grounded theory method to systematically code and categorize the data to find meaningful patterns. A qualitative software package was used to move text into categories during data coding. Results: A wide range of symptoms were attributed to exertion both in daily lives and following cardiopulmonary exercise testing. While three core symptoms emerged (exhaustion, cognitive difficulties, and neuromuscular complaints), participants' descriptions were notable for their unique individual variations. Of 18 participants who responded to questions centered around symptoms following a cardiopulmonary exercise test, 17 reported that symptoms started within 24 h and peaked in severity within 72 h following the cardiopulmonary exercise test. Patients described post–exertional Malaise as interfering with their ability to lead a “normal” life. Conclusion: The experience of post–exertional Malaise in myalgic encephalomyelitis/chronic fatigue syndrome varies greatly between individuals and leads to a diminished quality of life. myalgic encephalomyelitis/chronic fatigue syndrome patients describe post–exertional Malaise as all-encompassing with symptoms affecting every part of the body, difficult to predict or manage, and requiring complete bedrest to fully or partially recover. Given the extensive variability in patients, further research identifying subtypes of post–exertional Malaise could lead to better targeted therapeutic options.
-
characterization of post exertional Malaise in patients with myalgic encephalomyelitis chronic fatigue syndrome
Frontiers in Neurology, 2020Co-Authors: Barbara J. Stussman, Ashley Williams, Joseph Snow, Angelique Gavin, Remle Scott, Avindra Nath, Brian WalittAbstract:Background: Myalgic encephalomyelitis/chronic fatigue syndrome is characterized by persistent and disabling fatigue, exercise intolerance, cognitive difficulty, and musculoskeletal/joint pain. Post-exertional Malaise is a worsening of these symptoms after a physical or mental exertion and is considered a central feature of the illness. Scant observations in the available literature provide qualitative assessments of post-exertional Malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome. To enhance our understanding, a series of outpatient focus groups were convened. Methods: Nine focus groups totaling 43 patients who reported being diagnosed with myalgic encephalomyelitis/chronic fatigue syndrome were held between November 2016 and August 2019. Focus groups queried post-exertional Malaise in daily life and participants' retrospective memory of post-exertional Malaise that followed an exercise provocation with a cardiopulmonary exercise test. Data analysis followed the grounded theory method to systematically code and categorize the data to find meaningful patterns. A qualitative software package was used to move text into categories during data coding. Results: A wide range of symptoms were attributed to exertion both in daily lives and following cardiopulmonary exercise testing. While three core symptoms emerged (exhaustion, cognitive difficulties, and neuromuscular complaints), participants' descriptions were notable for their unique individual variations. Of 18 participants who responded to questions centered around symptoms following a cardiopulmonary exercise test, 17 reported that symptoms started within 24 h and peaked in severity within 72 h following the cardiopulmonary exercise test. Patients described post-exertional Malaise as interfering with their ability to lead a "normal" life. Conclusion: The experience of post-exertional Malaise in myalgic encephalomyelitis/chronic fatigue syndrome varies greatly between individuals and leads to a diminished quality of life. myalgic encephalomyelitis/chronic fatigue syndrome patients describe post-exertional Malaise as all-encompassing with symptoms affecting every part of the body, difficult to predict or manage, and requiring complete bedrest to fully or partially recover. Given the extensive variability in patients, further research identifying subtypes of post-exertional Malaise could lead to better targeted therapeutic options.
Yuji Miyamoto - One of the best experts on this subject based on the ideXlab platform.
-
prophylactic effect of dexamethasone on regorafenib related fatigue and or Malaise a randomized placebo controlled double blind clinical study in patients with unresectable metastatic colorectal cancer kscc1402 hgcsg1402
Oncology, 2018Co-Authors: Hiroaki Tanioka, Yuji Miyamoto, Akihito Tsuji, Masako Asayama, Takeshi Shiraishi, Satoshi Yuki, Masahito Kotaka, Akitaka Makiyama, Mototsugu Shimokawa, Takayuki ShimoseAbstract:Background: Regorafenib is an oral multikinase inhibitor with a proven survival benefit for metastatic colorectal cancer patients. The KSCC1402/HGCSG1402 study investigated the prophylactic effect of oral dexamethasone (DEX) on regorafenib-related fatigue and/or Malaise. Patients and Methods: Patients who progressed after standard chemotherapy were randomized 1: 1 to a DEX group (2 mg/day; days 1–28) with regorafenib or a placebo group with regorafenib. The primary endpoint was the incidence of fatigue and/or Malaise, based on version 4.0 of the National Cancer Institute’s CTCAE (Common Terminology Criteria for Adverse Events). One of the secondary endpoints was the incidence of fatigue and/or Malaise based on the CTCAE assessed by patient-reported outcome (PRO). Results: The incidence of any grade of fatigue and/or Malaise assessed by the investigators was 58.8% in the DEX group and 61.1% in the placebo group (p = 0.8101), and that assessed by PRO was 47.2 and 58.3%, respectively (p = 0.3450). The incidence of grade ≥2 fatigue and/or Malaise, as assessed by the investigators, was 19.4% for the DEX group and 38.9% for the placebo group (p = 0.0695), and that assessed by PRO was 27.8 and 52.8%, respectively (p = 0.0306). Conclusion: Our results suggest that prophylactic oral DEX is clinically effective in improving regorafenib-related fatigue and/or Malaise.
-
a randomized double blind placebo controlled phase ii study of prophylactic dexamethasone dex therapy for fatigue and Malaise due to regorafenib in patient pts with metastatic colorectal cancer mcrc kscc1402 hgcsg1402
Journal of Clinical Oncology, 2016Co-Authors: Yuji Miyamoto, Hiroaki Tanioka, Akihito Tsuji, Masako Asayama, Takeshi Shiraishi, Satoshi Yuki, Masahito Kotaka, Akitaka Makiyama, Mototsugu Shimokawa, Yoshito KomatsuAbstract:10127Background: Regorafenib (REG) is an oral multikinase inhibitor with survival benefit in salvage line therapy for metastatic colorectal cancer (mCRC); fatigue and Malaise which are common adverse events (AEs) cause REG treatment discontinuation. Oral steroids are empirically used for treatment of cancer related fatigue, although there is only a few evidence. KSCC1402/HGCSG1402 is a phase II, randomized, double-blind, placebo-controlled study evaluating the prophylactic effects of oral dex on REG-related fatigue and Malaise for pts with mCRC. Methods: Eligibility included mCRC, objective failure of standard therapy, ECOG performance status 0 or 1. ≤ Grade 1 fatigue or Malaise was allowed to be enrolled in this study. Pts were 1:1 randomly assigned to an oral steroids group (dex 2 mg/day, 4 weeks) or a placebo (PLC) group with REG (160 mg/day, 3 weeks on/1 week off). The protocol period was scheduled for first 28 days of REG treatment. The primary endpoint was incidence of fatigue or Malaise (CTCAE ver....
Hiroaki Tanioka - One of the best experts on this subject based on the ideXlab platform.
-
prophylactic effect of dexamethasone on regorafenib related fatigue and or Malaise a randomized placebo controlled double blind clinical study in patients with unresectable metastatic colorectal cancer kscc1402 hgcsg1402
Oncology, 2018Co-Authors: Hiroaki Tanioka, Yuji Miyamoto, Akihito Tsuji, Masako Asayama, Takeshi Shiraishi, Satoshi Yuki, Masahito Kotaka, Akitaka Makiyama, Mototsugu Shimokawa, Takayuki ShimoseAbstract:Background: Regorafenib is an oral multikinase inhibitor with a proven survival benefit for metastatic colorectal cancer patients. The KSCC1402/HGCSG1402 study investigated the prophylactic effect of oral dexamethasone (DEX) on regorafenib-related fatigue and/or Malaise. Patients and Methods: Patients who progressed after standard chemotherapy were randomized 1: 1 to a DEX group (2 mg/day; days 1–28) with regorafenib or a placebo group with regorafenib. The primary endpoint was the incidence of fatigue and/or Malaise, based on version 4.0 of the National Cancer Institute’s CTCAE (Common Terminology Criteria for Adverse Events). One of the secondary endpoints was the incidence of fatigue and/or Malaise based on the CTCAE assessed by patient-reported outcome (PRO). Results: The incidence of any grade of fatigue and/or Malaise assessed by the investigators was 58.8% in the DEX group and 61.1% in the placebo group (p = 0.8101), and that assessed by PRO was 47.2 and 58.3%, respectively (p = 0.3450). The incidence of grade ≥2 fatigue and/or Malaise, as assessed by the investigators, was 19.4% for the DEX group and 38.9% for the placebo group (p = 0.0695), and that assessed by PRO was 27.8 and 52.8%, respectively (p = 0.0306). Conclusion: Our results suggest that prophylactic oral DEX is clinically effective in improving regorafenib-related fatigue and/or Malaise.
-
a randomized double blind placebo controlled phase ii study of prophylactic dexamethasone dex therapy for fatigue and Malaise due to regorafenib in patient pts with metastatic colorectal cancer mcrc kscc1402 hgcsg1402
Journal of Clinical Oncology, 2016Co-Authors: Yuji Miyamoto, Hiroaki Tanioka, Akihito Tsuji, Masako Asayama, Takeshi Shiraishi, Satoshi Yuki, Masahito Kotaka, Akitaka Makiyama, Mototsugu Shimokawa, Yoshito KomatsuAbstract:10127Background: Regorafenib (REG) is an oral multikinase inhibitor with survival benefit in salvage line therapy for metastatic colorectal cancer (mCRC); fatigue and Malaise which are common adverse events (AEs) cause REG treatment discontinuation. Oral steroids are empirically used for treatment of cancer related fatigue, although there is only a few evidence. KSCC1402/HGCSG1402 is a phase II, randomized, double-blind, placebo-controlled study evaluating the prophylactic effects of oral dex on REG-related fatigue and Malaise for pts with mCRC. Methods: Eligibility included mCRC, objective failure of standard therapy, ECOG performance status 0 or 1. ≤ Grade 1 fatigue or Malaise was allowed to be enrolled in this study. Pts were 1:1 randomly assigned to an oral steroids group (dex 2 mg/day, 4 weeks) or a placebo (PLC) group with REG (160 mg/day, 3 weeks on/1 week off). The protocol period was scheduled for first 28 days of REG treatment. The primary endpoint was incidence of fatigue or Malaise (CTCAE ver....
